Eric Warren - 21 Aug 2026 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Reporting relationship: Chief Commercial Officer
Issuer ticker: MLYS
Reported as of: 21 Aug 2026
Net transaction value: -$193,189
SEC form: 4
Accepted by SEC: 25 Aug 2026, 17:16:45 UTC
Prior SEC filing: 23 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Adam Levy, Attorney-in-fact

Key filing fact

Eric Warren filed Form 4 for Mineralys Therapeutics, Inc. (MLYS) on 25 Aug 2026.

Key facts

This page summarizes Eric Warren's Form 4 filing for Mineralys Therapeutics, Inc. (MLYS).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 25 Aug 2026, 17:16.

Change

Previous filing in this sequence was filed on 23 Jul 2026.
Current net transaction value: -$193,189.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001916048 Primary reporting owner

Warren Eric

Relationship: Chief Commercial Officer
Address: 150 N. RADNOR CHESTER ROAD, SUITE F200, RADNOR
Signature: /s/ Adam Levy, Attorney-in-fact
Signature date: 25 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MLYS transaction

Common Stock

Options Exercise

Transaction value
Shares: +7,437
Change %: +19%
Price: $13.24^*
Shares after: 45,837
Date: 21 Aug 2026
Ownership: Direct
Footnotes: F1

MLYS transaction

Common Stock

Sale

Transaction value: $193,189
Shares: -7,437
Change %: -16%
Price: $25.98
Shares after: 38,400
Date: 21 Aug 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MLYS transaction Derivative

Stock Option

Options Exercise

Transaction value
Shares: -7,437
Change %: -3%
Price: $0.000000^*
Shares after: 238,001
Date: 21 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,437
Exercise price: $13.24
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026.

Footnote F2

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.82 to $26.15. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

Footnote F3

The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.